- Home
- AGEN vs BDTX Comparison
AGEN vs BDTX Comparison
Compare AGEN & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | BDTX |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 116.8M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AGEN | BDTX |
|---|---|---|
| Price | $3.38 | $2.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $14.50 | $10.20 |
| AVG Volume (30 Days) | 486.5K | ★ 571.5K |
| Earning Date | 03-16-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 100.00 | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | ★ $42,877,086.00 | N/A |
| Revenue This Year | $61.42 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.89 | ★ $5.46 |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $1.38 | $1.20 |
| 52 Week High | $7.34 | $4.94 |
Technical Indicators
Market Signals| Indicator | AGEN | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 39.11 |
| Support Level | $2.91 | $1.93 |
| Resistance Level | $4.72 | $2.30 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 38.97 | 1.82 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.